Redeye provides its comment on Mendus’ Q2 2024 report. Data recently presented at EHA and ESMO Gyn confirmed vididencel’s mechanism of action. Further, the company will deliver readouts from ADVANCE II, CADENCE, and ALISON in the coming 12-18 months. Its estimated funding runway extends past several of these catalysts. We do some housekeeping in our model and valuation.